Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
D Capodanno, R Mehran, M Valgimigli… - Nature Reviews …, 2018 - nature.com
In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force
JM Guirguis-Blake, CV Evans, CA Senger… - Annals of internal …, 2016 - acpjournals.org
Background: Cardiovascular disease (CVD) is the leading cause of death in the United
States. Purpose: To update a systematic review about the benefits of aspirin for the primary …
States. Purpose: To update a systematic review about the benefits of aspirin for the primary …
[PDF][PDF] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
MF Piepoli, AW Hoes, S Agewall… - Polish Heart …, 2016 - journals.viamedica.pl
2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
[HTML][HTML] Guidelines: Editor's choice: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European …
The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …
for personal and educational use only. No commercial use is authorized. No part of the ESC …
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
C Baigent, L Blackwell, R Collins, J Emberson… - …, 2009 - researchonline.lshtm.ac.uk
BACKGROUND: Low-dose aspirin is of definite and substantial net benefit for many people
who already have occlusive vascular disease. We have assessed the benefits and risks in …
who already have occlusive vascular disease. We have assessed the benefits and risks in …
Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …
Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force
EP Whitlock, BU Burda, SB Williams… - Annals of internal …, 2016 - acpjournals.org
Background: The balance between potential aspirin-related risks and benefits is critical in
primary prevention. Purpose: To evaluate the risk for serious bleeding with regular aspirin …
primary prevention. Purpose: To evaluate the risk for serious bleeding with regular aspirin …
Antiplatelet agents for the treatment and prevention of coronary atherothrombosis
Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the …
The burden of cardiovascular disease (CVD) among patients with diabetes is substantial.
Individuals with diabetes are at 2-to 4-fold increased risk of cardiovascular events compared …
Individuals with diabetes are at 2-to 4-fold increased risk of cardiovascular events compared …
CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human …
X Pivot, A Manikhas, B Żurawski… - Journal of Clinical …, 2015 - ascopubs.org
Purpose CEREBEL compared the incidence of CNS metastases as first site of relapse in
patients with human epidermal growth factor receptor 2–positive metastatic breast cancer …
patients with human epidermal growth factor receptor 2–positive metastatic breast cancer …